Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SA55 Nasal Spray in Healthy People
NCT06048393Phase 1Unknown
- Sponsor
- Sinovac Life Sciences
- Start
- May 2023
- Primary completion
- Sep 2023
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SA55 with Placebo (2 arms). Primary endpoint: Safety and Tolerability of SA55 Nasal Spray at 1 month. Status: unknown.
02
Drugs
covid-19 antibody nasal spray
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06048393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048393.